Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-12-18 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2017年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2017 first extraordinary general meeting of shareholders of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the meeting date, voting procedures, attendance, and the voting results on specific proposals, including changes to a new product R&D project and amendments to the company bylaws. It also includes legal opinions confirming the legality and validity of the meeting and resolutions. The document is not a full report but an official announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2116 characters), consistent with an announcement rather than a full report.
2017-12-18 Chinese
2017年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2017 first extraordinary general meeting (临时股东大会) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the legality of the meeting's notice, attendance, voting procedures, and resolutions passed. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process and resolutions. It is not an announcement of voting results per se, but a legal opinion letter related to the shareholder meeting. Given the content and nature, this document fits best under the category of Regulatory Filings (RNS), as it is a legal compliance document related to corporate governance and shareholder meetings but does not fit other more specific categories like AGM Information or Declaration of Voting Results. The document length is under 5,000 characters, but it is a substantive legal opinion, not a mere announcement of a report publication. Therefore, the classification is RNS with high confidence.
2017-12-18 Chinese
关于收到药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (723 characters) from a company about receiving drug registration approvals from a regulatory authority (国家食品药品监督管理总局). It contains no financial data, no financial results, no management discussion, no voting results, no share transactions, no legal proceedings, and no detailed report content. It is a regulatory announcement about a non-financial matter (drug registration approval). The document length and content indicate it is not a full report but a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS).
2017-12-14 Chinese
关于公司部分在研药品审评进展的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (584 characters) from a company about progress in regulatory approval of some drugs under development. It states that the company has not yet received formal approval documents and will issue further announcements when available. There are no financial statements, no detailed report content, and no mention of an attached or published report. The document is a regulatory update about drug approval status, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a voting result, management change, or capital update. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-12-11 Chinese
东莞证券股份有限公司关于公司子公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the use of temporarily idle raised funds by a subsidiary of the company for cash management. It references regulatory requirements, fundraising details, approval procedures, and risk controls related to the use of raised funds. The document is not a full annual or interim financial report, nor is it an earnings release or a simple announcement. It is a specialized report focused on the audit and verification of the use of raised funds, consistent with an Audit Report / Information filing. The length (5068 characters) and content indicate it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2017
2017-11-30 Chinese
关于子公司使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding the use of temporarily idle raised funds by its subsidiary for cash management. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, details the amount and purpose of the cash management, and includes approvals from the board, independent directors, and supervisors. The document is about the company's fundraising capital usage and management, specifically the use of idle raised funds for cash management, but it does not contain financial statements or detailed financial results. It is a regulatory announcement about capital usage and compliance with fundraising regulations rather than a financial report or earnings release. The document length is about 4862 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's fundraising capital usage and management activities.
2017-11-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.